Literature DB >> 26294719

Prognostic relevance of MYD88 mutations in CLL: the jury is still out.

Panagiotis Baliakas1, Anastasia Hadzidimitriou2, Andreas Agathangelidis3, Davide Rossi4, Lesley-Ann Sutton1, Jana Kminkova5, Lydia Scarfo3, Sarka Pospisilova5, Gianluca Gaidano4, Kostas Stamatopoulos6, Paolo Ghia7, Richard Rosenquist1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26294719      PMCID: PMC4598193          DOI: 10.1182/blood-2015-05-648634

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.

Authors:  Katherine I Lin; Constantine S Tam; Michael J Keating; William G Wierda; Susan O'Brien; Susan Lerner; Kevin R Coombes; Ellen Schlette; Alessandra Ferrajoli; Lynn L Barron; Thomas J Kipps; Laura Rassenti; Stefan Faderl; Hagop Kantarjian; Lynne V Abruzzo
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

2.  SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients.

Authors:  S Jeromin; S Weissmann; C Haferlach; F Dicker; K Bayer; V Grossmann; T Alpermann; A Roller; A Kohlmann; T Haferlach; W Kern; S Schnittger
Journal:  Leukemia       Date:  2013-09-12       Impact factor: 11.528

3.  Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Silvia Rasi; Valeria Spina; Alessio Bruscaggin; Sara Monti; Carmela Ciardullo; Clara Deambrogi; Hossein Khiabanian; Roberto Serra; Francesco Bertoni; Francesco Forconi; Luca Laurenti; Roberto Marasca; Michele Dal-Bo; Francesca Maria Rossi; Pietro Bulian; Josep Nomdedeu; Giovanni Del Poeta; Valter Gattei; Laura Pasqualucci; Raul Rabadan; Robin Foà; Riccardo Dalla-Favera; Gianluca Gaidano
Journal:  Blood       Date:  2012-12-13       Impact factor: 22.113

4.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

5.  Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome.

Authors:  Alejandra Martínez-Trillos; Magda Pinyol; Alba Navarro; Marta Aymerich; Pedro Jares; Manel Juan; María Rozman; Dolors Colomer; Julio Delgado; Eva Giné; Marcos González-Díaz; Jesús M Hernández-Rivas; Enrique Colado; Consolación Rayón; Angel R Payer; Maria José Terol; Blanca Navarro; Victor Quesada; Xosé S Puente; Ciril Rozman; Carlos López-Otín; Elías Campo; Armando López-Guillermo; Neus Villamor
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

6.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

7.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

8.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

9.  Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Authors:  Panagiotis Baliakas; Anastasia Hadzidimitriou; Lesley-Ann Sutton; Eva Minga; Andreas Agathangelidis; Michele Nichelatti; Athina Tsanousa; Lydia Scarfò; Zadie Davis; Xiao-Jie Yan; Tait Shanafelt; Karla Plevova; Yorick Sandberg; Fie Juhl Vojdeman; Myriam Boudjogra; Tatiana Tzenou; Maria Chatzouli; Charles C Chu; Silvio Veronese; Anne Gardiner; Larry Mansouri; Karin E Smedby; Lone Bredo Pedersen; Kirsten van Lom; Véronique Giudicelli; Hana Skuhrova Francova; Florence Nguyen-Khac; Panagiotis Panagiotidis; Gunnar Juliusson; Lefteris Angelis; Achilles Anagnostopoulos; Marie-Paule Lefranc; Monica Facco; Livio Trentin; Mark Catherwood; Marco Montillo; Christian H Geisler; Anton W Langerak; Sarka Pospisilova; Nicholas Chiorazzi; David Oscier; Diane F Jelinek; Nikos Darzentas; Chrysoula Belessi; Frederic Davi; Richard Rosenquist; Paolo Ghia; Kostas Stamatopoulos
Journal:  Lancet Haematol       Date:  2014-11-03       Impact factor: 18.959

10.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia.

Authors:  P Baliakas; A Hadzidimitriou; L-A Sutton; D Rossi; E Minga; N Villamor; M Larrayoz; J Kminkova; A Agathangelidis; Z Davis; E Tausch; E Stalika; B Kantorova; L Mansouri; L Scarfò; D Cortese; V Navrkalova; M J J Rose-Zerilli; K E Smedby; G Juliusson; A Anagnostopoulos; A M Makris; A Navarro; J Delgado; D Oscier; C Belessi; S Stilgenbauer; P Ghia; S Pospisilova; G Gaidano; E Campo; J C Strefford; K Stamatopoulos; R Rosenquist
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

  10 in total
  11 in total

1.  Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.

Authors:  C Baer; F Dicker; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2016-11-14       Impact factor: 11.528

2.  Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.

Authors:  Aaron M Goodman; Michael Choi; Matthew Wieduwilt; Carolyn Mulroney; Caitlin Costello; Garrett Frampton; Vincent Miller; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2017-04-27

Review 3.  MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.

Authors:  Miguel Alcoceba; María García-Álvarez; Alejandro Medina; Rebeca Maldonado; Verónica González-Calle; María Carmen Chillón; María Eugenia Sarasquete; Marcos González; Ramón García-Sanz; Cristina Jiménez
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

4.  Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.

Authors:  Panagiotis Baliakas; Sabine Jeromin; Michalis Iskas; Anna Puiggros; Karla Plevova; Florence Nguyen-Khac; Zadie Davis; Gian Matteo Rigolin; Andrea Visentin; Aliki Xochelli; Julio Delgado; Fanny Baran-Marszak; Evangelia Stalika; Pau Abrisqueta; Kristina Durechova; George Papaioannou; Virginie Eclache; Maria Dimou; Theodoros Iliakis; Rosa Collado; Michael Doubek; M Jose Calasanz; Neus Ruiz-Xiville; Carolina Moreno; Marie Jarosova; Alexander C Leeksma; Panayiotis Panayiotidis; Helena Podgornik; Florence Cymbalista; Achilles Anagnostopoulos; Livio Trentin; Niki Stavroyianni; Fred Davi; Paolo Ghia; Arnon P Kater; Antonio Cuneo; Sarka Pospisilova; Blanca Espinet; Anastasia Athanasiadou; David Oscier; Claudia Haferlach; Kostas Stamatopoulos
Journal:  Blood       Date:  2019-01-02       Impact factor: 22.113

5.  Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Authors:  Lesley-Ann Sutton; Emma Young; Panagiotis Baliakas; Anastasia Hadzidimitriou; Theodoros Moysiadis; Karla Plevova; Davide Rossi; Jana Kminkova; Evangelia Stalika; Lone Bredo Pedersen; Jitka Malcikova; Andreas Agathangelidis; Zadie Davis; Larry Mansouri; Lydia Scarfò; Myriam Boudjoghra; Alba Navarro; Alice F Muggen; Xiao-Jie Yan; Florence Nguyen-Khac; Marta Larrayoz; Panagiotis Panagiotidis; Nicholas Chiorazzi; Carsten Utoft Niemann; Chrysoula Belessi; Elias Campo; Jonathan C Strefford; Anton W Langerak; David Oscier; Gianluca Gaidano; Sarka Pospisilova; Frederic Davi; Paolo Ghia; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

6.  TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Authors:  Emma Kennedy; Eve Coulter; Emma Halliwell; Nuria Profitos-Peleja; Elisabeth Walsby; Barnaby Clark; Elizabeth H Phillips; Thomas A Burley; Simon Mitchell; Stephen Devereux; Christopher D Fegan; Christopher I Jones; Rosalynd Johnston; Tim Chevassut; Ralph Schulz; Martina Seiffert; Angelo Agathanggelou; Ceri Oldreive; Nicholas Davies; Tatjana Stankovic; Triantafillos Liloglou; Chris Pepper; Andrea G S Pepper
Journal:  Blood       Date:  2021-06-03       Impact factor: 22.113

7.  Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia.

Authors:  Panagiotis Baliakas; Theodoros Moysiadis; Anastasia Hadzidimitriou; Aliki Xochelli; Sabine Jeromin; Andreas Agathangelidis; Mattias Mattsson; Lesley-Ann Sutton; Eva Minga; Lydia Scarfò; Davide Rossi; Zadie Davis; Neus Villamor; Helen Parker; Jana Kotaskova; Evangelia Stalika; Karla Plevova; Larry Mansouri; Diego Cortese; Alba Navarro; Julio Delgado; Marta Larrayoz; Emma Young; Achilles Anagnostopoulos; Karin E Smedby; Gunnar Juliusson; Oonagh Sheehy; Mark Catherwood; Jonathan C Strefford; Niki Stavroyianni; Chrysoula Belessi; Sarka Pospisilova; David Oscier; Gianluca Gaidano; Elias Campo; Claudia Haferlach; Paolo Ghia; Richard Rosenquist; Kostas Stamatopoulos
Journal:  Haematologica       Date:  2018-09-27       Impact factor: 9.941

8.  Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.

Authors:  Natalie Galanina; Rafael Bejar; Michael Choi; Aaron Goodman; Matthew Wieduwilt; Carolyn Mulroney; Lisa Kim; Huwate Yeerna; Pablo Tamayo; Jo-Anne Vergilio; Tariq I Mughal; Vincent Miller; Catriona Jamieson; Razelle Kurzrock
Journal:  Cancers (Basel)       Date:  2018-12-21       Impact factor: 6.639

9.  MYD88 mutations predict unfavorable prognosis in Chronic Lymphocytic Leukemia patients with mutated IGHV gene.

Authors:  Shu-Chao Qin; Yi Xia; Yi Miao; Hua-Yuan Zhu; Jia-Zhu Wu; Lei Fan; Jian-Yong Li; Wei Xu; Chun Qiao
Journal:  Blood Cancer J       Date:  2017-12-15       Impact factor: 11.037

10.  Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.

Authors:  Wen Shuai; Pei Lin; Paolo Strati; Keyur P Patel; Mark J Routbort; Shimin Hu; Peng Wei; Joseph D Khoury; M James You; Sanam Loghavi; Zhenya Tang; Hong Fang; Beenu Thakral; L Jeffrey Medeiros; Wei Wang
Journal:  Blood Cancer J       Date:  2020-08-26       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.